×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
OTCMKTS:AGNPF

Algernon Pharmaceuticals News Headlines

$2.68
-0.15 (-5.30%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.68
$2.76
50-Day Range
$2.68
$4.44
52-Week Range
$2.50
$10.85
Volume
373 shs
Average Volume
2,324 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Get Algernon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter.

AGNPF Media Mentions By Week

AGNPF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AGNPF
News Sentiment

1.38

0.87

Average
Medical
News Sentiment

AGNPF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AGNPF Articles
This Week

2

1

AGNPF Articles
Average Week



AGNPF Stock News Headlines Today

SourceHeadline
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Closing of Public Offering of Units
finance.yahoo.com - July 4 at 5:57 PM
MarketBeat logoAlgernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Up 52.1% in June
americanbankingnews.com - July 4 at 2:20 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Pricing of Public Offering of Units
finance.yahoo.com - June 27 at 8:29 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
finance.yahoo.com - June 22 at 8:04 AM
finance.yahoo.com logoAlgernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
finance.yahoo.com - June 21 at 12:01 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Public Offering of Units
finance.yahoo.com - June 15 at 5:58 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough
finance.yahoo.com - May 5 at 8:24 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study
finance.yahoo.com - April 26 at 7:28 AM
proactiveinvestors.com.au logoAlgernon Pharmaceuticals completes enrollment in its Phase 2 Study of Ifenprodil for IPF and chronic cough
proactiveinvestors.com.au - March 3 at 6:17 PM
finance.yahoo.com logoThe Power Play by The Market Herald Releases New Interviews With Algernon Pharmaceuticals, Adastra Holdings and C3 Metals
finance.yahoo.com - February 23 at 2:23 PM
proactiveinvestors.com logoAlgernon Pharmaceuticals begins manufacturing Repirinast and launches new chronic kidney disease research program
proactiveinvestors.com - February 23 at 9:22 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
finance.yahoo.com - February 23 at 9:22 AM
seekingalpha.com logoAlgernon finishes enrollment in phase 2 trial of Ifenprodil for lung disease
seekingalpha.com - February 4 at 11:24 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
finance.yahoo.com - February 4 at 11:24 AM
proactiveinvestors.com logoAlgernon Pharmaceuticals granted Ifenprodil patent for idiopathic pulmonary fibrosis in Canada
proactiveinvestors.com - January 28 at 12:14 PM
seekingalpha.com logoAlgernon Pharma secures Canadian patent for ifenprodil for idiopathic pulmonary fibrosis
seekingalpha.com - January 28 at 7:11 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis
finance.yahoo.com - January 28 at 7:11 AM
proactiveinvestors.com logoAlgernon Pharmaceuticals includes novel salt forms of DMT in its recent IP patent applications
proactiveinvestors.com - January 24 at 1:31 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
finance.yahoo.com - January 24 at 7:57 AM
seekingalpha.com logoAlgernon Pharmaceuticals files for phase 1 DMT stroke study approval in UK
seekingalpha.com - January 19 at 1:37 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
finance.yahoo.com - January 19 at 8:37 AM
proactiveinvestors.com logoAlgernon Pharmaceuticals receives positive feedback from US FDA on Phase 2b Ifenprodil chronic cough study
proactiveinvestors.com - January 14 at 4:01 PM
seekingalpha.com logoFDA gives positive feedback to Algernon Pharma for Phase 2b chronic cough study
seekingalpha.com - January 14 at 4:01 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Issues Compensation Options
finance.yahoo.com - January 4 at 1:42 PM
proactiveinvestors.com logoAlgernon Pharmaceuticals completes manufacturing of Psychedelic Drug DMT for Phase 1 and 2 study
proactiveinvestors.com - December 10 at 4:16 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
finance.yahoo.com - December 2 at 7:21 AM
proactiveinvestors.com logoAlgernon Pharmaceuticals appoints former Medicure financial chief James Kinley as CFO
proactiveinvestors.com - November 30 at 12:44 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces New Chief Financial Officer
finance.yahoo.com - November 30 at 7:34 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
finance.yahoo.com - November 24 at 10:21 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Share Consolidation
finance.yahoo.com - November 17 at 9:15 PM
finance.yahoo.com logoThe Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News
finance.yahoo.com - November 1 at 8:33 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
finance.yahoo.com - November 1 at 10:32 AM
finance.yahoo.com logoAlgernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
finance.yahoo.com - October 26 at 3:13 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
finance.yahoo.com - October 21 at 8:32 AM
finance.yahoo.com logoThe Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News
finance.yahoo.com - October 15 at 12:28 PM
finance.yahoo.com logoAlgernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
finance.yahoo.com - October 13 at 12:22 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
finance.yahoo.com - October 8 at 7:59 AM
finance.yahoo.com logoHagens Berman: Law Firm Investigating Permanent Injuries and Disfigurement from Botched CoolSculpting Procedures
finance.yahoo.com - October 5 at 11:34 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces the Appointment of Dr. Mark Williams to the Board of Directors
finance.yahoo.com - September 22 at 10:04 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study
finance.yahoo.com - September 22 at 10:04 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
finance.yahoo.com - September 20 at 7:38 AM
benzinga.com logoAlgernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company's DMT Program at the International Microdose DMT Conference
benzinga.com - September 11 at 2:01 AM
proactiveinvestors.com logoAlgernon Pharmaceuticals "very excited" by preclinical data on DMT candidate
proactiveinvestors.com - September 9 at 7:55 AM
finance.yahoo.com logoAlgernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
finance.yahoo.com - September 7 at 8:00 AM
finance.yahoo.com logoLeading DMT Companies to Take Stage at Molecular Masterclass: DMT Conference
finance.yahoo.com - September 1 at 5:46 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant
finance.yahoo.com - August 11 at 9:21 AM
proactiveinvestors.com logoAlgernon Pharmaceuticals unlocking the value of medicine through repurposed drugs
proactiveinvestors.com - August 10 at 7:02 PM
finance.yahoo.com logoAlgernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College
finance.yahoo.com - August 9 at 8:55 AM
investorplace.com logoAlgernon Pharmaceuticals Inc (AGNPF)
investorplace.com - August 3 at 10:57 PM
finance.yahoo.com logoMicrodose Is Pleased to Announce the DMT Conference: A Molecular Masterclass
finance.yahoo.com - July 27 at 7:34 AM
Get Algernon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter.

This page (OTCMKTS:AGNPF) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.